CDK15

Across TCGA pan-cancer cohorts, CDK15 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CDK15 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher CDK15 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CDK15 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

BRCA, KIRP, and LIHC are the cancer types where CDK15 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.115	0.578	.002	24	view →
KIRP	DFS	Median	All	0.122	0.767	.001	6	view →
LIHC	DFS	Median	II,III,IV	0.044	0.414	<.001	3	view →
UCEC	DFS	Median	All	0.953	0.628	.041	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CDK15–BRCA (OS)

Open the BRCA breakdown →